Heron Therapeutics, Inc.
HRTX
$2.11
-$0.06-2.77%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -28.06% | 175.56% | 47.50% | -192.25% | 70.53% |
| Total Depreciation and Amortization | -5.16% | 0.00% | -9.36% | -6.97% | -3.64% |
| Total Amortization of Deferred Charges | -29.67% | -20.42% | 161.81% | 2.86% | -14.11% |
| Total Other Non-Cash Items | 8.77% | -32.86% | -58.63% | 150.02% | -25.44% |
| Change in Net Operating Assets | 21.15% | -531.19% | 224.31% | 66.09% | -220.11% |
| Cash from Operations | 24.70% | -449.45% | 173.22% | 51.62% | -487.62% |
| Capital Expenditure | 82.92% | -48.03% | 32.34% | -- | -- |
| Sale of Property, Plant, and Equipment | 55.56% | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -80.55% | 173.32% | 63.91% | 110.09% | 114.86% |
| Cash from Investing | -80.09% | 187.61% | 93.85% | 60.25% | 114.46% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 2,921.43% | -97.22% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -200.00% | 650.00% |
| Cash from Financing | -84.87% | 2,921.43% | -97.15% | 4,372.73% | -94.47% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -10,809.84% | -99.17% | 456.35% | 74.91% | -33.08% |